london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

The effect of intravitreal injection of bevacizumab on subfoveal choroidal thickness in patients with diabetic macular edema

Session Details

Session Title: FP-14 Vascular Diseases and Diabetic Retinopathy IV

Session Date/Time: Saturday 13/09/2014 | 16:30-18:00

Paper Time: 16:38

Venue: Boulevard F

First Author: : R.Leite PORTUGAL

Co Author(s): :    N. Gomes   L. Mendonça   K. Sousa   R. Gentil   G. Santos   F. Vaz

Abstract Details

Purpose:

To evaluate the effect of intra-vitreal injection (IVI) of Bevacizumab (BVCZ) on choroidal thickness (CT) in patients with diabetic macular edema (DME).

Setting:

Department of Ophthalmology, Hospital de Braga, Braga, Portugal.

Methods:

Retrospective observational study including patients with DME who received at least 3 consecutive 1.25 mg IVI of BVCZ with no other therapeutic procedure in the six months preceding the first injection. CT was measured using spectral-domain OCT before the first injection (t0), 4 weeks after the third injection (t1) and 4 weeks after the fourth injection (t2). We analyzed the change in choroidal and foveal retinal thickness before and after treatment with IVI of BVCZ.

Results:

We analyzed 88 eyes of 88 patients with DME. Eighteen of these eyes met the required criteria for the number of injections and treatment intervals. Mean patient age was 63,9±12,2 years for the entire patient population and 63,5±7,8 years for the BVCZ group. Foveal retinal thickness showed a modest negative correlation with CT. Patients who received 3 IVI of BVCZ had a decrease in foveal retinal thickness from 419 μm to 339 μm 4 weeks after the last injection (p=0.010). Those who received 4 IVI also had a decrease in their foveal thickness from 449 μm to 352 μm 4 weeks after the last injection (p=0.142) There was a slight decrease in CT in eyes receiving 3 or more IVI of BVCZ, which failed to reach statistically significance. CT decreased from 208 μm to 199 μm (p=0.099) in eyes with 3 IVI and from 189 μm to 179 μm (p=0.166) in patients who had 4 IVI.

Conclusions:

Our results failed to show a significant decrease in CT of patients with DME who underwent treatment with IVI of BVCZ. CT does not seem to change significantly after treatment with this drug.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy